Product

Pyronaridine-Artesunate

Aliases

Pyronaridine- artesunate (Pyramax) 540 mg/180 mg

1 clinical trial

1 indication

Indication

Clinical trial

Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 Plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)

Status: Recruiting, Estimated PCD: 2024-09-18